WS #16566
Sanofi and AstraZeneca both reported significant earnings beats, with Sanofi raising its full-year guidance on strong Dupixent sales and AstraZeneca posting a 93.8% EPS beat. These results underscore the defensive resilience of the healthcare sector, as high-margin blockbuster drugs continue to drive growth even in a mixed macroeconomic environment. This rotation into quality healthcare earnings provides a counter-narrative to the tech-heavy market volatility.
Pharma Earnings Beats
Sanofi and AstraZeneca both reported significant earnings beats, with Sanofi raising its full-year guidance on strong Dupixent sales and AstraZeneca posting a 93.8% EPS beat. These results underscore the defensive resilience of the healthcare sector, as high-margin blockbuster drugs continue to drive growth even in a mixed macroeconomic environment. This rotation into quality healthcare earnings provides a counter-narrative to the tech-heavy market volatility.